Concert Pharmaceuticals Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
Go back to Concert Pharmaceuticals Reports First Quarter 2015 Financial Results
May 8, 2015 3:08 PM EDT
Roth Capital affirms Concert Pharmaceuticals, Inc. (CNCE) at Buy and moves its price target from $19 up to $22 following Q1 results and corporate update issued by the company ahead of the opening bell Friday.
Analyst Joseph Pantginis noted that CNCE reported Q1 loss of $0.48 per share, versus the firm's loss estimate of $0.28 per share.
Pantginis commented, While the stock... More
May 8, 2015 8:56 AM EDT
Concert Pharma (NASDAQ: CNCE) reported Q1 EPS of ($0.48), $0.04 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $2.7 million.
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
...
More
